Serum apoptosis markers in acute liver failure: a pilot study

Clin Gastroenterol Hepatol. 2007 Dec;5(12):1477-83. doi: 10.1016/j.cgh.2007.08.007. Epub 2007 Oct 29.

Abstract

Background & aims: We sought to determine whether circulating apoptotic markers are altered in acute liver failure (ALF), differ with etiology, or predict clinical outcome in this condition.

Methods: Serum levels of soluble Fas (sFas), tumor necrosis factor-alpha (TNF-alpha), hepatocyte growth factor (HGF), and interleukin-6 (IL-6) were measured in 67 acute liver failure patients, as well as controls. In a subset of the groups, we measured serum M-30 antigen, an exposed neoepitope from caspase cleavage. We also assessed M-30 immunoreactivity in liver tissue of ALF patients and controls.

Results: Median levels for TNF-alpha, HGF, IL-6, and M-30 antigen were at least 10-fold greater in ALF than in hepatitis C virus or normal controls (P < .0001). Median day 1 sFas, day 3 sFas, and day 1 HGF levels varied according to etiology of acute liver failure (P = .004, P = .011, and P = .019, respectively), with values for drug-induced liver injury and acetaminophen-related ALF higher than other etiologies. Median M-30 antigen levels were significantly higher in patients who were transplanted and/or died (2183 U/L) than spontaneous survivors (1004 U/L) (P = .026). M-30 immunoreactivity in liver tissue was significantly greater in ALF patients than HCV controls (P = .004).

Conclusions: TNF-alpha, HGF, IL-6, and M-30 antigen were significantly elevated in ALF. High levels of sFas and HGF might help to confirm a diagnosis of drug-induced liver injury or acetaminophen-related ALF. Higher levels of M-30 antigen are associated with poor clinical outcomes in ALF.

Publication types

  • Comparative Study
  • Research Support, N.I.H., Extramural

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Apoptosis / physiology*
  • Biomarkers / blood
  • Enzyme-Linked Immunosorbent Assay
  • Female
  • Follow-Up Studies
  • Hepatocyte Growth Factor / blood*
  • Humans
  • Immunohistochemistry
  • Interleukin-6 / blood*
  • Liver / metabolism
  • Liver / pathology*
  • Liver Failure, Acute / blood*
  • Liver Failure, Acute / pathology
  • Male
  • Middle Aged
  • Pilot Projects
  • Prognosis
  • Severity of Illness Index
  • Tumor Necrosis Factor-alpha / blood*
  • fas Receptor / blood*

Substances

  • Biomarkers
  • FAS protein, human
  • Interleukin-6
  • Tumor Necrosis Factor-alpha
  • fas Receptor
  • Hepatocyte Growth Factor